STTK (Shattuck Labs) Long-Term Debt: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STTK Shattuck Labs Inc STTK
42 GF Score
Price $7.42
GF Value $1.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Shattuck Labs Long-Term Debt?

Shattuck Labs STTK +4.80% 42 Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates STTK with a GF Score™ of 42/100 and a GF Value™ of $1.05 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Shattuck Labs's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Shattuck Labs  (NAS:STTK) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Shattuck Labs Long-Term Debt Related Terms

Shattuck Labs Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Shattuck Labs's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shattuck Labs Long-Term Debt Chart

Shattuck Labs Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Shattuck Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STTK
42GF Score
Shattuck Labs Inc STTK
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Shattuck Labs (STTK) has a Long-Term Debt of $0.00 Mil as of Mar. 2026.
Is Shattuck Labs' Long-Term Debt too high?
Shattuck Labs' current Long-Term Debt is $0.00 Mil. Overall, Shattuck Labs has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shattuck Labs' Long-Term Debt compare to ACHV and CRMD?
Shattuck Labs' Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Shattuck Labs's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shattuck Labs stock overvalued right now?
Based on GuruFocus' analysis, Shattuck Labs (STTK) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $7.42 — trading 606.7% above its estimated fair value. The current Long-Term Debt is $0.00 Mil. Shattuck Labs' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Shattuck Labs (STTK), the current Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shattuck Labs (STTK) Overvalued in 2026?

Based on GuruFocus' analysis, Shattuck Labs stock appears to be overvalued. The current stock price of $7.42 is trading 606.7% above its estimated GF Value™ of $1.05. GuruFocus considers Shattuck Labs to be Significantly Overvalued.

Key valuation signals for STTK:

  • Long-Term Debt: $0.00 Mil
  • GF Value™: $1.05 vs. price of $7.42 (606.7% above fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the STTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shattuck Labs Business Description

Address 500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
42GF Score

Get the complete analysis for STTK

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.42
Price
$1.05
GF Value